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Abstract 
Perivascular adipose tissue (PVAT), the adipose tissue that surrounds most of the vasculature, has emerged as an 
active component of the blood vessel wall regulating vascular homeostasis and affecting the pathogenesis of ath‑
erosclerosis. Although PVAT characteristics resemble both brown and white adipose tissues, recent evidence sug‑
gests that PVAT develops from its own distinct precursors implying a closer link between PVAT and vascular system. 
Under physiological conditions, PVAT has potent anti‑atherogenic properties mediated by its ability to secrete various 
biologically active factors that induce non‑shivering thermogenesis and metabolize fatty acids. In contrast, under 
pathological conditions (mainly obesity), PVAT becomes dysfunctional, loses its thermogenic capacity and secretes 
pro‑inflammatory adipokines that induce endothelial dysfunction and infiltration of inflammatory cells, promoting 
atherosclerosis development. Since PVAT plays crucial roles in regulating key steps of atherosclerosis development, 
it may constitute a novel therapeutic target for the prevention and treatment of atherosclerosis. Here, we review the 
current literature regarding the roles of PVAT in the pathogenesis of atherosclerosis.
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Background
Atherosclerosis is an inflammatory disease of the arter-
ies characterized by lipid accumulation within the artery 
walls. In humans, atherosclerotic plaques are usually 
found in the aorta, the coronary arteries and cerebral 
arteries, but also in peripheral arteries [1]. Advanced 
atherosclerotic plaques grow large to block blood flow 
resulting in various cardiovascular diseases (CVD) 
including coronary heart disease (CHD), angina, carotid 
artery disease, peripheral artery disease and chronic kid-
ney disease. Even though epidemiological and experi-
mental studies have strengthened the pathophysiological 
associations between obesity and atherosclerosis [2, 3], 
the underlying causes of atherosclerosis remain unclear. 
Growing evidence suggest that atherosclerotic plaque 
formation begins with endothelial damage caused by 
factors released from adipose tissues to the circulation, 
promoting adhesions of circulating immune cells that ini-
tiate the progression of atherosclerosis [4, 5].
Adipose tissue is distributed throughout the body. 
In general, there are two main types of adipose tissues: 
white adipose tissue (WAT) and brown adipose tissue 
(BAT) [6, 7]. Historically, adipose tissue was recognized 
as a protective pad for neighboring organs. In recent 
years however, adipose tissue has emerged as a major 
endocrine organ which produces large amount of adi-
pokines such as leptin, resistin, adiponectin and inflam-
matory cytokines [8–10]. Excess lipid accumulation in 
WAT causes adipocyte hypertrophy and dysfunction, 
resulting in enhanced secretion of deleterious adipokines 
and inflammatory cytokines into the circulation, that 
subsequently impair the function of the endothelium 
in blood vessels [11, 12]. Unlike WAT, BAT can take-up 
lipids to produce heat by uncoupling oxidation on mito-
chondrial electron transportation chain, which contrib-
utes to clearance of plasma lipids and prevents storage 
of lipids in WAT and other organs [13]. Dysfunctional 
WAT might be positively associated with atherosclero-
sis development, whereas activation of BAT may protect 
against atherosclerosis development. This hypothesis is 
Open Access
Cardiovascular Diabetology
*Correspondence:  zsjiang2005@163.com 
1 Institute of Cardiovascular Disease, Key Lab for Arteriosclerology 
of Hunan Province, University of South China, Hengyang 421001, China
Full list of author information is available at the end of the article
Page 2 of 20Qi et al. Cardiovasc Diabetol  (2018) 17:134 
strengthened by evidence of reduced hypercholester-
olaemia and atherosclerosis development upon BAT 
activation with β3-adrenergic receptor stimulation 
in hyperlipidemic mice [14]. Key milestones in BAT 
research are the discovery of active BAT sites in adult 
humans and the “browning” ability of WAT by hormonal 
or cold temperature stimuli [15–18]. Browning of WAT 
is now defined as the third type of adipose tissue—beige 
adipose tissue (BeAT), which is characterized by high 
expression of the brown adipocyte marker uncoupling 
protein-1 (UCP-1) [19].
In addition to the classification of adipose tissues by 
their coloration, adipose tissues can also be catego-
rized according to their anatomic locations. Perivas-
cular adipose tissue (PVAT) is a type of adipose tissue 
which surrounds the blood vessels. Recently, PVAT 
characteristics resemble both BAT and WAT, it has 
been considered as an active component of the blood 
vessel walls, and involved in vascular homeostasis [20]. 
There are intensive studies regarding the relationship 
between PVAT and atherosclerosis [21, 22]. In this 
review, we will focus on the roles of PVAT in the patho-
physiological progress of atherosclerosis (both pro- and 
anti-atherogenic effect) and its potential as a target for 
therapeutic intervention (Fig. 1).
The characteristics of PVAT
Although surrounding adipose tissue is abundant in vas-
cular trees of animals and humans, it was ignored for a 
long time. As pointed recently by Caroline Pond: “human 
Fig. 1 The role of PVAT in the regulation of atherosclerosis. In normal physiological state, PVAT secret protective adipokines and bioactive molecules 
such as adiponectin and NO maintain vascular homeostasis. Under pathology condition, unbalanced PVAT‑derived adipokines, chemokines and 
cytokines targets many cell types including ECs, macrophage, T cells and SMCs involved in endothelial dysfunction, immune cells infiltration, 
smooth muscle cell migration and proliferation which are predominantly implicated in the pathological process of atherosclerosis
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and comparative anatomists still regarded it as too incon-
sistent and inconsequential to be worthy of topographic, 
functional or evolutionary study. It was always dissected 
off vessels and lymph nodes in pickled prosections” [23]. 
In 1982, Hausman and Richardson first described the his-
tochemical and ultrastructural criteria of preadipocytes 
in perivascular location [24]. In 1984, de Souza et  al. 
[25] described that the vessel’s sheaths and lamellae are 
formed by networks of collagen and elastic fibers. The 
perivascular area is filled by connective tissue, delimiting 
lobules of adipose tissue. Since then, there had been little 
research on the function of perivascular connective tis-
sue until 1991 when Soltis and Cassis defined PVAT and 
its influence on rat aortic smooth muscle responsiveness 
[26]. In 2001, Okamoto et al. [27] reported the invasion of 
leukocytes into the perivascular adipose layer in response 
to angioplasty injury of coronary arteries, suggesting that 
PVAT inflammation might be associated with CVD.
In humans, the severity in spontaneous atherosclero-
sis may vary not only in different arteries but also in dif-
ferent segments of the same blood vessel [28]. Previous 
research, mainly in rodents, indicates that the appear-
ance of PVAT varies by anatomic and metabolic context 
[29]. Current reports indicate that PVAT in the thoracic 
aorta is more similar to BAT, while PVAT in the abdomi-
nal aorta resembles both WAT-like and BAT-like pheno-
types, which is referred as BeAT. Other smaller arteries 
are surrounded by WAT-like PVAT [30]. In humans, the 
coronary arteries are the most atherosclerosis-prone 
arteries with abundant of PVAT surrounding. In mice 
however, there is no PVAT surrounding the coronary 
arteries [30]. Of interest, mouse coronary arteries are 
resistant to atherosclerosis development [31], suggesting 
that the existence of PVAT may be associated with ath-
erosclerosis development. However, the occurrence and 
development of atherosclerosis is influenced by many 
factors that determine the vascular susceptibility for 
atherosclerotic risk factors. Indeed, different segments 
of the aorta are differentiated from the distinct origins. 
It is unclear whether the atherosclerosis susceptibility of 
artery is associated with its origins. Similarly, different 
types of adipose tissue located at different anatomical 
depots may have their unique precursors.
The adipocytes in classical WAT such as subcutaneous 
WAT may be differentiated from mesenchymal stem cells 
(MSCs) in perivascular regions [32, 33]. Tang et al. [34] 
found that the majority of postnatal white adipocytes 
derived from prenatally peroxisome proliferator-activated 
receptor-γ (PPAR-γ) expressing lineage cells that are 
located in the stromal vasculature fraction (SVF). Gene-
expression profiles showed that these PPAR-γ express-
ing lineage cells have a unique molecular signature and 
are phenotypically distinct from adipocytes and other 
stromal vasculature cells. Specifically, the SVF of harbor-
ing PPAR-γ expressing cells resembles blood vessels with 
expressions of mural cell markers smooth muscle actin 
(SMA), platelet-derived growth factor receptor,  β  poly-
peptide (PDGFRβ), and neural/glial antigen 2 (NG2). 
By using PDGFRβ or SM22Cre-mediated lineage stud-
ies, Tang et  al. [34] further confirmed that PDGFRβ-
expressing, but not SM22-expressing mural cells have 
adipogenic potential. Rodeheffer et al. [35] further iden-
tified that only  CD29hi:CD34+  cells in SVF (about 59% 
cells in SVF) are of significant adipogenic differentiation 
populations. It is unknown whether mature brown adi-
pocytes are differentiated from  CD29hi:CD34+ precur-
sors in SVF. Lee et al. [36] reported that white adipocytes 
and β3 agonist-induced brown adipocytes in abdominal 
WAT originated from the PDGFRα:CD34+Sca-1+ cells 
[36]. The same group further documented that cold stress 
rapidly induces de novo brown adipogenesis in classic 
BAT. Genetic lineage tracing demonstrated that newly 
generated brown adipocytes are derived from resident 
PDGFRα progenitors [37]. Additionally, interscapular 
brown adipocytes may share the same origin with skeletal 
muscle. Using in vivo fate mapping, Seale et  al. [38, 39] 
reported that brown, but not white adipocytes arise from 
 Myf5+ precursors, which was thought to be expressed 
only in the myogenic lineage. Even though PVAT shares 
many biochemical and morphological characteristics 
with classical brown or white adipocytes, it is unknown 
whether the adipocytes in PVAT are differentiated from 
precursors in WAT or BAT as described above.
Similar to classical brown adipocytes, beige adipo-
cytes express UCP-1. However, brown and beige adi-
pocytes may have different developmental origins [40]. 
Genetic deletion of PPAR-γ in vascular smooth muscle 
cells (VSMCs) using SM22a-Cre knock in tool, unex-
pectedly showed a phenotype that the adipose tissues in 
mesenteric region and peri-aortic region are completely 
undeveloped. However, adipose tissue in gonadal, sub-
cutaneous, interscapular WAT and BAT were intact 
[41]. This mouse model strongly supports the notion 
that there are separate development origins for adipose 
tissues in different anatomic depots. Later, to address 
the cellular heterogeneity of different adipose tissue 
types, Long et al. [42] demonstrated the similarities and 
differences between brown and beige adipocytes in mice 
by applying translating ribosome affinity purification 
technology. Consistent with the report by Chang et  al. 
[41], Long et al. [42] documented a smooth muscle-like 
gene expression signature (Acta2,  Tagln,  Myh11,  Myl9, 
and  Cnn1) in beige adipocytes, but not in interscapu-
lar classical brown adipocytes. By exposing Myh11-
GFP/tdTomato mice to cold temperature for 2  weeks, 
which is known to induce browning in WAT, it was 
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demonstrated that beige adipocytes arise from a 
 Myh11+ precursor. Additionally, UCP1 positive lipid 
droplet-containing adipocytes were found in PRDM16-
overexpressing mature VSMCs subjected to adipogenic 
cocktail and followed by treatment with triiodothyro-
nine, rosiglitazone and insulin, indicating that mature 
VSMCs can give rise to adipocytes with a thermogenic 
gene-expression signature [42]. Whereas the above 
studies [41, 42] suggest that VSMCs might be the ori-
gin of some thermogenic adipocytes in PVAT or WAT, 
further studies are needed to clarify whether thermo-
genic adipocytes arise from  SM22a+ or  Myh11+ mature 
VSMCs or SMC-like stem cells. Therefore, these reports 
indicate that PVAT is distinct from the adipose tissues 
at other locations since the different origins.
As research focusing on PVAT characteristics was 
largely ignored until 2001, accumulating evidence sug-
gests that PVAT is an active component of the blood 
vessel wall and contributes to vascular homeostasis by 
producing a number of biologically active molecules 
including adipokines (e.g. leptin, adiponectin, omentin, 
visfatin, resistin, apelin), cytokines/chemokines (e.g. 
interleukin-6, IL-6; tumor necrosis factor-α, TNF-α; 
monocyte chemoattractant protein-1, MCP-1), gaseous 
molecules (e.g. nitric oxide, NO, and hydrogen sulfide, 
 H2S), prostacyclin, angiotensin-1 to 7 (Ang 1–7), Ang 
II, methyl palmitate, and reactive oxygen species (ROS) 
[20, 43–45]. Thus, PVAT-derived bioactive factors 
coordinately contribute to vascular tone regulations. 
PVAT-derived relaxing factors (PVRF) such as adi-
ponectin, NO,  H2S, prostacyclin, angiotensin1-7 and 
methyl palmitate can promote vasodilation by targeting 
the medial and the endothelial layer of blood vessels, 
whereas the PVAT-derived contractile factors (PVCF) 
such as Ang II, ROS and other unidentified factors may 
induce blood vessel constriction [46]. Therefore, PVAT 
is actively involved in the regulation of blood pressure. 
Circadian rhythm is one of the major physiological reg-
ulators of blood pressure, and is controlled by suprachi-
asmatic nucleus (SCN) where the circadian clock genes 
are coordinately expressed according to the light cycles. 
Recently, it was reported that circadian clock genes 
are expressed in PVAT which transcriptionally con-
trol local production of Ang II, suggesting that PVAT 
is involved in circadian regulation of blood pressure. 
Nevertheless, it remains unknown whether production 
of other PVRFs and PVCFs is also controlled in a circa-
dian manner [47].
PVAT and atherosclerosis
Atherosclerosis is a progressive chronic metabolic dis-
order which is characterized by endothelial dysfunc-
tion, lipid deposition and inflammation infiltration [48]. 
It is well-accepted that shear stress-induced endothelial 
dysfunction/damage is the initial step of the atheroscle-
rosis development. Accordingly, atherosclerotic plaques 
are most frequently found at the bifurcation sites of the 
aorta/arteries [49]. Findings indicating that adhesions 
of circulatory inflammatory cells to the dysfunctional 
endothelium trigger cholesterol accumulation in the 
artery wall support the “inside to outside” theory of ath-
erosclerosis development [50]. The atherosclerotic plaque 
is initiated and progressed in the neointima layer with 
intact internal elastic lamina, and the plaques are barely 
found in the media and adventitia layers [51]. However, 
the function of the endothelium of blood vessels is gradu-
ally deteriorating during the obesity process. Quesada 
et  al. demonstrated that PVAT‐derived inflammatory 
mediators may adversely influence atherosclerotic plaque 
formation and stability [52]. Interestingly, PVAT also has 
been shown a protective role in endothelial dysfunction 
hypercholesterolemic LDL receptor deficient mice, sug-
gesting that PVAT-derived factors might be involved in 
the regulation of endothelial function [53]. Thus, PVAT 
might actively influence atherosclerosis development in 
an “outside to inside” manner.
Anti‑atherogenic effects of PVAT
Atherogenesis is a closely associated with endothelial 
dysfunction that is characterized by reduced bioavailabil-
ity of nitric oxide (NO). NO is produced by endothelial 
NO synthase (eNOS) which possess multiple anti-ather-
ogenic properties including control of vascular smooth 
muscle proliferation and inhibition of platelet aggrega-
tion, leucocyte adhesion and vascular inflammation [54]. 
Recent studies show that eNOS is expressed not only in 
the endothelium but also in PVAT [55]. Moreover, PVAT-
derived NO can be directly visualized in  situ with fluo-
rescence imagine [56]. In healthy individuals, basal NO 
production by small arteries is reduced when PVAT is 
removed, suggesting that PVAT contributes to vascu-
lar NO production [57]. Furthermore, PVAT can secret 
adiponectin which is known to normalize endothelial 
function by a mechanism that involves an increment in 
eNOS phosphorylation [58]. Another mechanism by 
which PVAT protects against atherosclerosis develop-
ment involves the thermogenic ability result in clearance 
of plasma lipids from vasculature, another critical factor 
in atherosclerosis pathogenesis.
Previous evidence suggest different phenotypes of 
PVAT at different anatomical locations [59–61]. In the 
abdominal PVAT, white adipocytes are more abundant, 
whereas thoracic PVAT contains more brown adipocytes 
[61, 62]. Interestingly, microarray analysis revealed that 
the gene expression patterns in thoracic PVAT are almost 
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identical to those of interscapular BAT in mice [61]. In 
contrast to BeAT, thoracic PVAT maintains a BAT-like 
phenotype under high fat diet feeding [61]. These find-
ings suggest that thoracic PVAT more closely resembles 
classical BAT than BeAT in terms of morphology and 
function. Under physiological conditions, both WAT 
and BAT share anti-atherogenic properties. WAT acts 
as a lipid depot to prevent the rise lipids in the circula-
tion, while BAT consumes large amounts of fatty acids 
via thermogenesis [63]. Indeed, activation of BAT pro-
tects against atherosclerosis development in mice [14]. 
Though the PVAT at different locations might show dis-
tinct morphology and function, it is accepted that PVAT 
inhibits atherosclerosis under physiological conditions 
via its thermogenic and fatty acid-scavenging capabilities. 
Recent studies have demonstrated that the cold exposure 
induce activation of thermogenesis in PVAT, accom-
panied by attenuation of the atherosclerotic process in 
 apoE−/− mice, whereas such protection is lost in mice 
where PVAT is absent [41], suggesting that the thermo-
genic properties of PVAT exert anti-atherogenic effects. 
In addition, PVAT-derived adipokines such as adiponec-
tin, can suppress plaque formation and reduce inflamma-
tion indicating that the endocrine function of PVAT also 
have athero-protective effects [64]. Furthermore, grow-
ing evidence indicates that some endogenous bioactive 
gaseous molecules such as  H2S, can alleviate atheroscle-
rosis [65]. Although PVAT can secret such anti-athero-
genic gaseous molecules, further investigation is needed 
to evaluate whether this might be another mechanism 
underlying the anti-atherogenic effects of PVAT. Taking 
together, the above evidence indicate that PVAT has anti-
atherogenic properties involving improved endothelial 
function, metabolic and inflammatory responses.
Pro‑atherogenic effects of PVAT
Pediatric epidemiological studies documented that  ath-
erosclerosis begins in childhood [66]. The Bogalusa Heart 
Study showed that atherosclerotic lesions were found 
in young arteries aged 6–30 years [67]. The PESA (Pro-
gression of Early Subclinical Atherosclerosis) study indi-
cated that the extent of subclinical atherosclerosis was 
present in 71% of men and 48% of women aged from 40 
to 54  years [28]. These population studies strongly sug-
gest that atherosclerotic lesions start at very young age. 
BAT exists in human infants, and is gradually replaced by 
WAT with growth. However, BAT is still present in adult 
humans and may be activated under specific condition 
such as cold stimuli [68]. PVAT resembles either WAT or 
BAT and emerged as a regulator involved in pathogenesis 
of vascular lesion formation.
Ketonen et al. reported that obesity-induced endothe-
lial dysfunction in C57BL/6 mice is caused by enhanced 
expression of inflammatory cytokines and increased 
oxidative stress in PVAT [69]. In accord, Manka et  al. 
found that transplantation of PVAT from obese mice 
to  LDLR−/− mice exacerbated lesion formation with 
increased inflammatory cell infiltration and pathological 
angiogenesis in adventitia [70]. Obesity is associated with 
increased risk for CVD and with remodeling of adipose 
tissues. It is clear that inflammation in adipose tissue 
under obese condition is highly related to atherosclero-
sis development [71]. Expansion of WAT and BAT due 
to obesity result in elevated basal lipolytic rate leading 
to enhanced release of fatty acids accompanied by secre-
tion of pro-inflammatory factors that contribute to the 
development of insulin resistance (IR) and inflammation 
[11, 12, 72]. Additionally, IR leads to reduced clearance 
of fatty acids, which are deposited ectopically in mus-
cle or liver, and enhances IR in turn [73]. Furthermore, 
fatty acids can activate Toll-like receptor (TLR) 2 and 
TLR4 which modulate the NF-κB signaling pathway in 
macrophages that play key roles in atherosclerosis devel-
opment [74, 75]. Obesity-induced dysfunctional BAT 
undergoes a whitening switch, a phenotype which aggra-
vates atherogenesis as evidenced by lipid accumulation 
and mitochondrial dysfunction [76, 77]. During obesity, 
PVAT, regardless of its phenotype or anatomical location, 
also becomes dysfunctional and releases elevated levels 
of pro-inflammatory factors, cytokines and chemokines 
directly to the vascular wall, inducing endothelial dys-
function and inflammation [78]. As obesity likely induces 
whitening of BAT-like PVAT, the thermogenic capacity of 
PVAT is reduced. Thus, obesity-induced PVAT dysfunc-
tion may cause endothelial dysfunction, immune cells 
infiltration, VSMCs migration and proliferation which 
contribute to atherosclerosis development. Since PVAT 
is adjacent to blood vessels, the paracrine effects of dys-
functional PVAT might have more pronounced con-
sequences to atherosclerosis progression than adipose 
tissues in other depots.
PVAT‑derived adipokines and atherosclerosis
Adipocyte derived adipokines can modulate several 
physiological functions including food intake, glucose 
and lipid metabolism, thermogenesis, neuroendocrine 
function, blood pressure, and immunity [79]. Dysfunc-
tional adipocytes under overweight/obesity conditions 
contribute to unbalanced release of adipokines which 
has been suggested as a potential link between PVAT 
and atherosclerosis. Atherosclerosis progression is tightly 
orchestrated by endothelial function, cholesterol trans-
port, inflammation, immune response and VSMCs pro-
liferation, all are intimately associated with adipokines 
(summarized in Table 1). Adiponectin is known to pro-
tect against atherosclerosis development. Adiponectin 
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can suppress the generation of ROS [80], down-regulate 
the expression of adhesion molecules [81], and inhibit 
apoptosis [82]. Moreover, recent evidence empha-
sized that adiponectin is a negative modulator of innate 
immune response and can down-regulate the release of 
pro-inflammatory factors, TLR4 expression [83], pro-
mote cholesterol efflux from macrophage [84], and 
polarization of macrophages towards M2 phenotype 
[85]. Consistently, as an (AMP-activated protein kinase) 
AMPK agonist, adiponectin has anti-atherogenic prop-
erties [86–89]. In addition, vaspin, apelin and omentin-1 
exert protective effects on atherosclerosis by inhibiting 
ROS generation, enhancing cholesterol efflux and reduc-
ing activation of inflammatory macrophages, respectively 
[90–92]. Unlike adiponectin, detrimental adipokines 
such as leptin, chemerin and resistin have been associ-
ated with endothelial cell proliferation, angiogenesis, 
ROS generation and adhesion molecules expression 
[93–95]. Particularly, leptin was shown to promote mac-
rophage infiltration, VSMCs proliferation and release of 
TNF-α and IL-6 [96, 97]. Also, resistin facilitates mac-
rophage recruitment in adipose tissue and atheroscle-
rotic plaque [98], while leukocyte recruitment was shown 
to correlate with chemerin [99]. Clinical evidence indi-
cating unbalanced adipokine profile (decreased serum 
adiponectin, apelin, omentin-1 levels and increased 
serum leptin, resistin, chemerin concentrations) in coro-
nary atherosclerosis disease patients [100–105], further 
highlight the importance of adipokines as biomarkers for 
atherosclerosis.
Adipokines released by PVAT include adiponectin 
[106], leptin [107], resistin [108], visfatin [109], chemerin 
[110], lipocalin-2 (LCN2) [58], fatty acid binding pro-
tein (FABP) [111], which show direct evidence of PVAT-
derived adipokines have effects on the progression of 
atherosclerosis. Accumulating evidence demonstrates a 
potential role of PVAT-derived adipokines in atheroscle-
rosis. PVAT-derived adiponectin was shown to inhibit 
atherosclerosis by promoting macrophage autophagy 
via the Akt/FOXO3 signaling pathway [64] and to 
improve NO production by activating eNOS via PI3/
Akt phosphorylation [112]. In contrast, PVAT-derived 
leptin promotes VSMC to undergo a switch into a syn-
thetic phenotype via a p38 MAPK-dependent pathway 
which can be inhibited by leptin antagonist [107]. Lep-
tin released by PVAT has also been shown to exacerbate 
coronary endothelial dysfunction through the protein 
kinase C-beta pathway [113]. Three newly discovered 
adipokines: visfatin, LCN-2, FABP represent a further 
link between adipose tissue and atherosclerosis due to 
their ability to activate macrophages and regulate their 
phenotypes [114–116]. Visfatin has been demonstrated 
to be secreted by PVAT and stimulate VSMCs prolifera-
tion in a dose- and time-dependent manner via extracel-
lular signal-regulated kinase (ERK) 1/2 and p38 MAPK 
signaling pathways [109]. FABP4 locally produced by 
perivascular fat increased gene expression of inflamma-
tory markers in a dose-dependent manner and was an 
independent predictor of the severity of coronary steno-
sis [111]. Nevertheless, further studies are warranted to 
Table 1 Role of adipokines in atherosclerosis
Adipocytokines Role Function References
Adiponectin Protective Improve endothelial dysfunction
Modulate immune response
Promote cholesterol efflux
Polarization of macrophages
AMPK agonist
[80–82]
[83]
[84]
[85]
[86]
Vaspin Protective Inhibit ros generation [90]
Apelin Protective Enhance cholesterol efflux [91]
Ometin‑1 Protective Reduce activation of inflammatory macrophages [92]
Leptin Detrimental Promote endothelial dysfunction
Promote macrophage infiltration
VSMCS proliferation
[93]
[94]
[97]
Resistin Detrimental Promote endothelial dysfunction
Facilitate macrophage recruitment
[94]
[98]
Chemerin Detrimental Promote endothelial dysfunction
Promote leukocyte recruitment
[95]
[99]
Visfatin Detrimental VSMCS proliferation
Macrophage maturation
Polarization of macrophages
[109]
[114]
[115]
FABP Detrimental Activate inflammatory macrophages [116]
LCN‑2 Detrimental Activate inflammatory macrophages [116]
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show whether PVAT could secret all of those adipokines 
shown in Table  1 which have multiple functions during 
atherosclerosis process.
Taking together, under physiological condition, PVAT 
exerts anti-atherogenic effects partly through reducing 
inflammation, which are largely mediated by protective 
adipokines, such as adiponectin. However, in the set-
ting of obesity in which inflammatory adipokines, such 
as leptin, are increased, the protective actions of PVAT 
are diminished. Thus, the balance between pro- and 
anti-inflammatory adipokines secreted from adipocytes 
determines the effects of PVAT on vascular remodeling 
processes.
PVAT inflammation in atherosclerosis
Numerous reports support the key role of the inflam-
matory response in atherosclerosis development [117]. 
Leukocyte recruitment and pro-inflammatory cytokines 
participate pivotally in the early phase of atherogenesis. 
It is now well accepted that dysfunctional adipose tissue 
in conditions of obesity is a critical source of inflamma-
tory factors that impact the cardiovascular system and 
promote atherosclerosis. In dysfunctional adipose tis-
sue, secretion of adiponectin is reduced, whereas secre-
tion of pro-inflammatory cytokines is increased, leading 
to enhanced local inflammation and substantially affect-
ing cardiovascular function and morphology. Whereas 
earlier studies on inflammation in atherosclerosis have 
focused on neo-intima and atherosclerotic plaques, it is 
becoming clear that the inflammatory response in the 
pathogenesis of atherosclerosis not only occurs in the 
luminal side of the vessels, but also in the adventitial 
side [118]. A recent study demonstrated that PVAT and 
adventitial inflammation precede endothelial dysfunction 
and atherosclerotic plaque formation [119]. Interestingly, 
growing evidence suggests that macrophage infiltration 
is more pronounced in the adventitia than in the intima 
in animal models, making PVAT inflammation a critical 
player in atherosclerotic development [120, 121].
PVAT adipocytes and immune cells release vasoac-
tive molecules such as adiponectin and IL-10 which have 
anti-inflammation effect under physiological conditions 
[83, 122]. Also, microarray analysis of perimesenteric 
adipocytes revealed increased expression of certain anti-
inflammatory genes including tumor necrosis factor 
α-induced protein 6 (TAIP6) and suppressor of cytokine 
signaling 2 (SOCS2) [123]. On the other hand, transplan-
tation of PVAT on the carotid artery resulted in increased 
vascular remodeling after wire-induced adventitial 
inflammation and angiogenesis in LDLR knockout ani-
mals [70]. Like other adipose depots, PVAT expands and 
become dysfunctional, then infiltrated with inflamma-
tion under pathological conditions [124–126]. Initiation 
of inflammation in PVAT results in enhanced secretion 
of chemokines and cytokines, such as MCP-1 which 
recruits cells, monocytes and macrophages. Immune 
cells derived IL-6 and TNF-α induce endothelium dam-
age and increased expression of vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion mole-
cule-1 (ICAM-1), consequently triggering atherosclerosis 
development [127, 128]. Importantly, the direct contact 
of PVAT with the vessels enables significant anti- or pro-
inflammatory signaling, mediated by immune cells, adi-
pokines, chemokines and cytokines, that play key roles in 
atherosclerosis development.
PVAT‑derived chemokines and cytokines
Chemokines play crucial roles in initiation and regulation 
of inflammation, especially the immune response [129]. 
Chemokines are small molecules (8–12 kDa) which can 
be divided into 4 canonical subclasses: C, CC, CXC, and 
 CX3C chemokines, based on the position of the N-termi-
nal cysteine [130]. Chemokines and their receptors are 
widely expressed in vascular cells, such as endothelial 
cells, VSMCs and leukocytes [130]. In particular, the role 
of the CCL2–CCR2, CCL5–CCR1/CCR5 and  CX3CL1–
CX3CR1 chemokine axes has been well-established in 
atherogenesis [110, 131–135]. PVAT-derived chemokines 
induce recruitment of monocytes and T cells which 
in turn produce additional chemokines, resulting in 
enhanced infiltration of inflammatory cells in a positive 
feedback mechanism [136, 137]. Cytokines from dysfunc-
tional PVAT induce VSMCs proliferation, endothelial 
dysfunction, enhanced secretion of pro-inflammatory 
adipokines and suppressed release of anti-inflammatory 
adipokines [123, 138, 139]. Most evidence points to the 
key role of IFN-γ, IL-17, IL-6 and TNF-α in regulating 
this pathogenic process, whereas the opposing action 
of IL-10 can improve endothelial function via inhibition 
of NADPH-dependent oxidative stress and increased 
NO production [140, 141]. The role of chemokines and 
cytokines in atherosclerosis is summarized in Table 2.
Immune cells in PVAT
T cells
Immune cell infiltration is a key driver of PAVT inflam-
mation. In contrast to visceral fat, PVAT T cell infiltra-
tion may precede and exceed macrophage infiltration 
in animal models [142]. Perivascular T cells represent a 
morphologically and functionally heterogeneous cellular 
population. Both  CD4+ T helper (Th),  CD8+ T cytotoxic 
(Tc), T regulatory (Treg) and γ/δ T cells are present in 
PVAT [132, 143, 144]. Th1, Tc1 and Th17 cells are pro-
atherogenic cells that secret pro-inflammatory cytokines, 
such as IFN-γ, TNF-α, IL-17 [145]. In contrast, Treg cells 
are atheroprotective cells that release anti-inflammatory 
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cytokines (IL-10) which play a critical role in immune 
homeostasis and prevent excessive immune responses 
[144, 146]. Interestingly, a subset of  CD8+ Treg cells con-
trol immune responses by affecting apoptosis and the 
function of adjacent vascular cells [147]. While other sub-
populations of T cells such as invariant natural killer T 
(iNKT) cells have been reported in PVAT, which mainly 
contribute to production of IFN-γ and TNF-α [148]. 
Finally, γ/δ T cells have been demonstrated to represent a 
substantial proportion of T cells in PVAT, but their func-
tional importance is not clear [149].
B cells
During atherosclerosis, B cells are primarily localized 
within the plaque and in artery tertiary lymphoid organs 
(ATLOs) [150]. The effects of B cell on atherosclerosis 
development are dependent on their subset, with B-1 
cells attenuating and B-2 cells aggravating atherosclero-
sis. B-1 cells exert anti-atherogenic activities via secretion 
of IgM, inhibiting the formation of foam cells, whereas 
B-2 cells stimulate Th1 cells and dendritic cells to play 
a pro-atherogenic role [151]. Little is known about the 
characteristics of B cells and their function in PVAT, but 
a recent study provides evidences that the majority of B 
cells in and around the aorta are derived from PVAT in 
mice [152]. In addition, a large proportion of these B cells 
belong to the B-1 subset which secret significantly greater 
numbers of IgM secreting cells than the aorta. Moreover, 
 ApoE−/− mice with B cell-specific knockout of the gene 
encoding the helix-loop-helix factor Id3, which is known 
to attenuate diet-induced atherosclerosis, have increased 
numbers of B-1 cells and increased IgM secreting cells 
in PVAT. Most important, immunostaining of PVAT on 
human coronary arteries identified fat associated lym-
phoid clusters (FALCs) harboring high numbers of B 
cells, and flow cytometry demonstrated the presence of T 
cells and B cells including B-1 cells [152]. Taken together, 
these finds demonstrated that PVAT harbors atheropro-
tective IgM-producing B-1 cells.
Macrophages
Resident adipose tissue macrophages present antigens 
to lymphocytes, phagocytize pathogens, release antimi-
crobial peptides, and attract other immune cells [153]. 
Macrophages constitute about 10–15% of stromal-vascu-
lar fraction, while a dramatic increase of up to 45–50% 
is observed during obesity [154]. In hypercholesterol-
aemia and hypertension, macrophages can accumulate 
in PVAT and release free radicals via NADPH oxidase 2 
(NOX2) even in the absence of obesity [155–157]. Under 
physiological conditions, M2 macrophages which pro-
duce IL-10 are dispersed in adipose tissues [158], while 
in pathological conditions, polarized M1 macrophages 
accumulate in crown-like structures surrounding adi-
pocytes and produce pro-inflammatory cytokines such 
as IL-6, IFN-γ and TNF-α [159, 160]. In PVAT, mac-
rophages play an important role in regulating T cell acti-
vation through antigen presentation and expression of 
Table 2 Role of chemokines and cytokines in atherosclerosis
Mediators Derived Function References
CCL2/
MCP‑1
Adipocytes Recruitment of T cells and monocytes
Macrophage infiltration
[130, 286]
[156]
CCL5/
RANTES
T cells, ECs
VSMCs, adipocytes
Recruitment of T cells and monocytes [130, 286]
CX3CL1 Monocytes
ECs
Recruitment of T cells and monocytes
Migration of VSMCs
Anti‑apoptosis and proliferative effects on monocytes and VSMCs
[130, 286]
[287]
[288, 289]
IFN‑γ Immune cells
NK cells
Activation of monocytes/macrophages
Polarization of immune cells
Impair endothelium‑dependent relaxation
VSMCs proliferation and apoptosis
[290]
[290]
[137]
[291]
IL‑6 Macrophage
T cells, ECs
Adipocytes
Impair endothelium‑dependent relaxation
Superoxide production and endothelium dysfunction
Th17 cell differentiation with pro‑inflammatory effects on ECs and VSMCs
VSMCs migration and proliferation
[292]
[293, 294]
[295]
[296]
IL‑17 Th cells Expression of adhesion molecules in ECs and VSMCs
Decreased NO production
Collage deposition
[297]
[298]
[299]
TNF‑α Immune cells
Adipocytes
Decrease eNOS expression, enhance ROS production
Increase endothelial adhesion molecules and chemokines
[143, 300]
[300]
IL‑10 Treg cells
Macrophage
DCs
Reduce oxidative stress
Increase production of NO
Inhibit activation of P38 MAPK
[141]
[141]
[122]
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co-stimulatory ligands [161]. Indeed, T cell-dependent 
responses may reciprocally regulate PVAT macrophage 
infiltration [162], indicating a bidirectional relationship 
between the T cells chemotaxis and macrophage infiltra-
tion in PVAT inflammation.
Dendritic cells (DC) and natural killer (NK) cells
Dendritic cells (DC) are the most efficient antigen pre-
senting cells, which are located primarily on the adven-
titia–PVAT border, but have also been reported within 
PVAT [132, 163]. A close relationship between DC and 
T cells has been demonstrated. During PVAT inflam-
mation, DC release inflammatory mediators (e.g. IL-1β, 
IL-6 and IL-23), promoting T cells to produce pro-
inflammatory cytokines such as IL-17, TNF-α and IFN-γ 
[123, 164]. Moreover, blocking the CD28/CD80/CD86 
co-stimulation axis between DC and T cells prevents 
PVAT inflammation [165]. Compared to DC, the role of 
NK cells in PVAT inflammation is less clear. As NK cells 
regulate macrophage polarization and insulin resistance 
through release of IFN-γ in visceral adipose tissue [166], 
further research focusing on the role of NK cells in PVAT 
is warrant.
Cellular and molecular contact between PVAT 
and the vessel wall in the progression 
of atherosclerosis
Pathological studies have revealed a defined series of 
changes in the vessel wall during atherogenesis includ-
ing endothelial dysfunction, inflammatory cells infiltra-
tion, foam cell formation, lipid overload, SMCs migration 
and proliferation and fibrous plaque formation. PVAT 
releases biologically active molecules and secretes adi-
opokines/cytokines that can modulate pathophysiologi-
cal process of atherosclerosis [20]. The possible role of 
PVAT in the initiation and progression of atherosclerosis 
is detailed below.
Lesion initiation—Endothelial dysfunction
The endothelium functions as a selective permeable 
barrier between blood and surrounding tissues. The 
endothelium also produces effector molecules that regu-
late key processes such as, inflammation, vascular tone, 
vascular remodeling and thrombosis [167]. It is well-
accepted that endothelial dysfunction is a hallmark fea-
ture of the initiation of atherosclerosis [168]. Damaged 
endothelium promotes atherosclerosis by increasing leu-
kocyte adhesion, vascular permeability to lipoproteins, 
platelet aggregation and generation of cytokines [169]. 
As mentioned earlier, PVAT releases a number of protec-
tive agents under physiological conditions, such as NO, 
 H2S and adiponectin. These are well-known as protec-
tive endothelium-derived factors with anti-atherogenic 
properties. Indeed, the lack of NO and  H2S acceler-
ates the progression of atherosclerosis [170, 171]. Dur-
ing obesity, PVAT-derived NO,  H2S and adiponectin are 
decreased in obese animals [172–174], and the hyper-
trophy of adipocytes in PVAT promotes endothelial 
dysfunction in relation to increased NADPH oxidase-
derived oxidative stress and enhanced inflammation [69]. 
But in a human research, their data suggest increased 
adiponectin expression in perivascular tissue which 
might a compensatory mechanism to preserve endothe-
lial function in obese patients [175]. For this point, there 
are some weaknesses of this study such as sample size, 
more rigorous investigations should be addressed.
Lesion development—Macrophage recruitment 
and activation, foam cell formation and plaque rupture
The impact of PVAT on experimental atherosclerotic 
lesion development has been less extensively examined. 
Under homeostatic conditions, the anti-inflammatory 
effects of PVAT predominate, and secretion of pro-
inflammatory paracrine agents is relatively low [176]. 
In one of the few studies available so far it was shown 
that PVAT-derived adiponectin was shown to suppress 
perivascular collar-induced carotid atherosclerotic lesion 
formation in high fat diet-fed  apoE−/− mice through 
increasing macrophage autophagy [64]. Macrophages 
accumulate in the vascular wall and take up modified 
lipoproteins (mainly oxidized-LDL) to form foam cells, 
a hallmark feature of early atherogenesis. This modifica-
tion presumably involves ROS, secretory phospholipases 
A2 (sPLA2) produced by ECs and macrophage [177, 178]. 
The rapid uptake of highly modified LDL particles by 
macrophages is related with ‘scavenger’ receptors CD36 
which is regulated by PPAR-γ [179, 180]. As clarified 
above, dysfunctional PVAT produces inflammatory adi-
pokines/cytokines such as leptin, TNF-α and IL-6, which 
induce endothelium production of VCAM-1, ICAM-1 
and MCP-1 promoting the adherence and migration of 
monocytes into the subendothelial layer of the intima 
[127, 128, 181, 182]. Once inside the intima, monocytes 
acquire characteristics of resident macrophages and 
secret pro-inflammatory cytokines such as IL-6, IFN-γ 
and TNF-α, aggravating recruitment of inflammatory 
cells, endothelial injury and LDL oxidation, then, accu-
mulation of the modified LDL particles in these mac-
rophages eventually turns into the foam cells [183]. On 
the other hand, our previous data showed that selec-
tive depletion of PVAT in mice with PPAR-γ deletion in 
SMCs was associated with impaired vascular thermoreg-
ulation, endothelial dysfunction [41]. Morover, we fur-
ther demonstrate that brown adipocyte-specific PPAR-γ 
deletion impairs PVAT development and enhances ath-
erosclerosis in mice suggesting that PPAR-γ could be a 
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pivotal link between PVAT and atherosclerosis lesion 
development [184]. In more advanced stages of athero-
sclerosis, macrophages induce apoptosis of VSMCs that 
requires a combination of at least Fas Ligand and NO 
[185, 186]. Finally, activated macrophages express effec-
tor molecules such as matrix mentalloproteinases that 
promote rupture of atherosclerotic plaques [187, 188]. 
Taken together, increased expression of inflammatory 
adipokines/cytokines in dysfunctional PVAT enhances 
endothelial dysfunction, leading to macrophage recruit-
ment and activation that promote vascular lesion forma-
tion and progression.
Neointima formation—Smooth muscle cells proliferation 
and migration
Neointima are characterized by accumulated VSMC and 
VSMC-derived extracellular matrix which contribute to 
further stenosis. The effects of PVAT on intimal SMC 
infiltration have been investigated after transplantation of 
thoracic PVAT to wire-injured carotid arteries, where the 
presence of PVAT accelerated neointimal formation in 
an MCP-1 dependent manner [70]. Also, transplantation 
of PVAT derived from transgenic mice overexpressing 
adipose tissue-specific angiopoietin like 2 (ANGPTL2) 
accelerated neointimal hyperplasia induced by wire 
injury of the femoral artery, which was attenuated by 
transplantation of PVAT from  ANGPTL2−/− mice [189]. 
Moreover, inflamed PVAT increases VSMC proliferation 
in a TGF-β dependent manner, suggesting that TGF-β 
released from PVAT can potentiate neointima formation 
[190]. Furthermore, as reviewed elsewhere [136], PVAT-
derived factors such as leptin, viafastin, TNF-α, IL-6 and 
IL-8, promote VSMC proliferation and migration. How-
ever, it is noteworthy, that the role of VSMC migration 
and proliferation in atherosclerosis remains controver-
sial, and proliferation of VSMC is mainly considered as a 
stabilizer of atherosclerotic plaques rather than contrib-
uting to their formation [191].
PVAT: link between atherosclerosis and diabetes
It is worth mentioning that atherosclerosis is closely 
associated with and accelerated by metabolic syndrome, 
especially diabetes. Because the metabolic syndrome 
occurs in most people with type 2 diabetes, its presence 
likely accounts for most of the increased incidence of 
CVD in type 2 diabetes [192]. Furthermore, the presence 
of diabetes increases the risk of CVD beyond that with 
metabolic syndrome alone distinguishes it from meta-
bolic syndrome [192]. Oxidative stress, inflammation and 
IR are key players in the development of atherosclerosis, 
diabetes and their complications. IR is a major feature of 
type 2 diabetes and develops in multiple organs, including 
skeletal muscle, liver, adipose tissue, and heart. Clinical 
hyperglycemia is always preceded by many years of IR 
which is associated with obesity [193]. Indeed, a substan-
tial proportion of diabetic patients are obese [194]. Adi-
pose tissue is main sources of free fatty acid (FFA) and 
pro-inflammatory molecules [195]. Hypertrophy of adi-
pose tissue release abundant FFA binding TLRs to phos-
phorylation of insulin receptor substrate-1 (IRS-1), result 
in the down-regulation of the glucose transporter-4 
(GLUT-4) and, hence, IR [196, 197]. Phosphorylated 
IRS-1 alters its ability to activate downstream PI3-kinase 
and Akt leads to eNOS inhibition and decreased NO 
production [196]. Furthermore, intracellular oxidation 
of stored FFA generates ROS leading to vascular inflam-
mation, advanced glycation end products (AGEs) synthe-
sis and protein kinase C (PKC) activation [198, 199]. The 
initial trigger vascular function in diabetes is the hyper-
glycemia related reduced NO bioavailability and accumu-
lation of ROS, leading to endothelial dysfunction [200]. 
Actually, overproduction of ROS by mitochondria is the 
causal link between high glucose concentration and bio-
chemical pathways of vascular complications in diabetes. 
Indeed, hyperglycemia-induced ROS production triggers 
several cellular mechanisms including AGEs sythesis, 
PKC activation, and NF-κB-mediated inflammation [199, 
201]. PKC and its downstream targets play a major role in 
vascular dysfunction. PKC not only trigger eNOS upcou-
pling [202–204] but also increase synthesis of endothe-
lin-1 favouring vasoconstriction and platelet aggregation 
[205]. Moreover, accumulation of superoxide anion also 
triggers up-regulation of pro-inflammatory genes MCP-
1, VCAM-1, and ICAM-1 via activation of NF-κB signal-
ing [199]. More interesting, glucose intolerance is related 
with down-regulated PPAR-γ in adipose tissue which 
impairs development of PVAT and enhances atheroscle-
rosis [184, 206]. Nonetheless, hyperglycemia and IR alone 
may not fully explain the persistent cardiovascular risk 
burden associated with type 2 diabetes. Exactly, normali-
zation of glycemia does not reduce macrovascular events 
suggesting that mediators of other risk factors other than 
glucose significantly participate to increase the residual 
cardiovascular risk in diabetic patients [207]. In this 
regard, adipose dysfunction, result in aberrant released 
adipokines/cytokines, oxidative stress, hypoxia and 
inflammation may be particular relevant [208]. One study 
has demonstrated that fed rat with fructose can induce 
the changes in PVAT fatty acyl composition and oxida-
tive stress biomarkers which are associated with vascular 
reactivity. The PVAT redox state was also modified by the 
fructose overload, as shown by a reduced activity of anti-
oxidant enzymes and augmented oxidative stress [209]. 
It has been proposed that dysfunction of PVAT is associ-
ated with reduced glucose transport by reducing muscle 
perfusion [210].
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As clarified above, dysfunctional adipose leads to an 
altered secretory profile. Adipokines and cytokines are 
link to IR, oxidative stress, inflammation or immune 
response [211–213]. Adiponectin released from PVAT 
has been reported to affect insulin sensitivity, inflamma-
tory responses, appetite, atherosclerosis [214]. In adi-
ponectin knockout mice, adiponectin deficiency reduced 
IRS-1-mediated insulin signaling, resulting in severe 
diet-induced IR [215]. Furthermore, in obese animals, 
administration of adiponectin has been found to improve 
insulin sensitivity and to decrease hyperglycemia and the 
level of fatty acids in the plasma [216, 217]. Enlargement 
of adipose tissue is accompanied by reduced expression 
of adiponectin and increased release of pro-inflamma-
tory cytokines such as TNF-α and IL-6 [214]. Whereas, 
another study has showed a causal relationship between 
high serum adiponectin levels and increased cardiovas-
cular mortality rate in patients with type 2 diabetes that 
pointing to an unexpected deleterious action [218]. The 
intrinsic biological nature underlying deleterious effect 
is difficult to understand or only to speculate. Whether 
adiponectin play a role in increasing atherosclerotic pro-
cesses is a possibility that deserves further, specifically 
designed studies. Conversely, in another study, leptin 
expression was increased in the PVAT, leading to inflam-
mation, fibrosis and vascularization, in patients undergo-
ing coronary artery bypass surgery [219]. Moreover, there 
is a correlation between increases in plasma leptin and IR 
and cardiac dysfunction in a type 2 diabetes model [220]. 
The effects of leptin leading to IR may be indirectly medi-
ated by the brain where it activates the sympathetic nerv-
ous system [221]. Another adipokine, resistin, has been 
described to increase TNF-α and IL-6 production [222]. 
In endothelial cells, resistin has been found to increase 
VCAM-1 and ICAM-1 expression [223]. Irisin, a new 
hormone released by adipose tissue may be involved in 
pro-atherogenic endothelial disturbances that accom-
pany obesity and T2DM [224]. Omentin-1, a novel adi-
pocytokine mainly expressed in visceral adipose tissue, 
has been found to inhibit the inflammatory response and 
improve insulin resistance as well as other obesity-related 
disorders. Recently, circulating and epicardial adipose 
tissue (EAT)-derived omentin-1 levels were reduced in 
patients with CAD. Furthermore, omentin-1 expres-
sion in patients with CAD was lower in EAT adjacent to 
coronary stenotic segments than non-stenotic segments. 
Whether EAT omentin-1 expression associated with 
local coronary atherosclerosis should be further clari-
fied [225]. Inflammatory cytokines such as TNF-α may 
be associated with obesity-related IR. In TNF-α defi-
cient obese mice had lower levels of circulating FFA and 
were protected from the obesity-related reduction in the 
insulin receptor signaling in muscle and fat tissues [226]. 
These findings demonstrated that TNF-α is an important 
mediator of IR in obesity through its effects on several 
important sites of insulin action. Taken together, adi-
pose tissue is a resource of multiple active molecules that 
influence the common pathogenesis of atherosclerosis 
and diabetes. PVAT attracts more attention as its unique 
location but more direct evidence should be shown to 
demonstrate its pivotal function in metabolic disease and 
cardiovascular system.
Therapeutic targeting on PVAT
PPAR‑γ agonist and the adiponectin axis
PPAR-γ is an important regulator of adipocyte func-
tion, with diverse effects on whole body glucose and 
lipid metabolism. Activation of PPAR-γ in a variety of 
tissues such as the liver and skeletal muscle ameliorates 
insulin resistance [227]. Evidence have demonstrated 
that loss of PVAT on PPAR-γ deletion in smooth mus-
cle cells or in BAT impairs intravascular thermoregula-
tion and enhances atherosclerosis, indicating PPAR-γ as 
a key mediator between PVAT and atherosclerosis [41, 
184]. Thiazolidinediones (TZD), including rosiglitazone 
and pioglitazone, are a class of anti-diabetic drugs that 
were reported to possess also anti-atherogenic and anti-
inflammatory effects [228]. More important, pioglitazone 
may offer a new effect on the whole vessel wall, promot-
ing the stability of advanced atherosclerotic plaques [52]. 
However, it should be noted that TZD use is associated 
with the risk of fluid retention which may exacerbate 
heart failure [229]. This highlights the need for better 
understanding of the tissue-specific effects of PPAR-γ, in 
order to target its signaling more effectively.
To date, adiponectin is one of the most studied adi-
pokines which is a known downstream target of PPAR-γ 
[230, 231]. A recent study group use TZD to stimulate 
adipogenesis in precursor cells emerging from from tho-
racic and abdominal aortic rings. They observed that 
cells emerging from the aortic ring take on adipocyte 
morphology, express adipocyte markers, and secrete adi-
ponectin suggesting TZD can not only promote perivas-
cular adipogenesis but also induce secretion by PVAT 
[232]. Numerous reports have identified a plethora of 
anti-inflammatory, insulin-sensitizing, and anti-oxidative 
roles for adiponectin. Indeed, PVAT-derived adiponec-
tin directly related to endothelial function [58], where 
it suppresses the generation of ROS [80], and down-
regulates adhesion molecules expression [81]. In addi-
tion, adiponectin inhibits atherosclerosis by aggravating 
macrophage autophagy [64]. Additionally, adiponectin 
induces M2 macrophage polarization while inhibiting 
inflammatory infiltration and reducing lipid content in 
adipose tissue [233]. Pharmaceutic adiponectin now still 
targeting its receptor and an oral adiponectin receptor 
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agonist have been demonstrated to improve insulin sensi-
tivity and glucose tolerance in mice [234], suggesting that 
signaling of adiponectin may be beneficial in vivo, but its 
significance in vascular disease remains to be evaluated.
GLP‑1 receptor agonists/analogues and DPP‑4 inhibitors
Glucagon-like peptide-1 (GLP-1) receptor agonists/
analogues or dipeptidyl peptidase-4 (DPP-4) inhibitors 
are anti-diabetic drugs also shown to have beneficial 
effects against vascular disease [235, 236]. Interestingly, 
adipose tissue also secretes low levels of GLP-1, which 
reduces lipid accumulation [237], increases the expres-
sion of adiponectin [238], and promotes M2 macrophage 
polarization [239]. The specific effects of these agents 
on PVAT and whether they can be involved in paracrine 
cross-talk between PVAT and the vascular wall are still 
questioned. DPP-4 enzymatically modifies GLP-1, facili-
tating its degradation and reducing its bioavailability. It 
is reasonable to assume that the effects of DPP4 inhibi-
tors on AT and CVD will derive from the concomitant 
potentiation of GLP-1 actions. But recent evidence indi-
cate that the effect of DPP-4 on adipose tissue and vascu-
lature are beyond GLP-1. DPP-4 that is able to modulate 
of endothelial progenitor cells, inflammatory pathway 
and ischemic response [240]. Hence, DPP-4 inhibitors 
exert its anti-atherogenic effect through not only GLP-1 
dependent way but also independent way. For specific 
target on PVAT, teneligliptin, a DPP-4 inhibitor attenu-
ated atherogenesis with alter the inflammatory pheno-
type in PVAT [241, 242]. Therefore, targeting of DPP4 
may be a crucial regulator of the cross-talk between 
PVAT and the vascular wall.
Browning of WAT 
An alternative therapeutic approach is to induce the 
formation of beige adipocytes in PVAT. Similar to clas-
sic brown adipocytes, beige adipocytes may also use tri-
glycerides for non-shivering thermogenesis [243]. Thus, 
browning of PVAT will likely contribute to lowering of 
plasma triglyceride levels and preventing atherosclero-
sis. Cold temperature and catecholamine stimulation 
are well-established approaches to induce browning of 
WAT [14, 244, 245]. In addition, numerous approaches/
stimuli that promote a brown-like phenotype are emerg-
ing, including activation of β3-adrenergic receptors 
[246], AMPK activation [247], inhibitors of Notch sign-
aling [248], lactate [249], gut microbiota [250], thyroid 
hormone [18], fibroblast growth factor 21 [251], bone 
morphogenetic protein (BMP) 4 [252, 253] and BMP7 
[253]. Furthermore, various components of the immune 
system including macrophages [254], eosinophils [255] 
and group 2 innate lymphoid cells (ILC2) [256] have been 
implicated to promote the browning process.
Anti‑inflammatory strategies
As described above, release of adipokines, chemokines 
and cytokines in dysfunctional PVAT potentially facili-
tates PVAT local inflammation and enhances atheroscle-
rosis progression. To date, there are no effective strategies 
that directly target PVAT local inflammation. Increasing 
anti-inflammatory adipokines, decreasing inflammatory 
cytokines or suppressing immune cells infiltration seems 
to be a promising approach to reduce inflammation in 
PVAT. The existing anti-inflammatory drugs, anti-TNF 
monoclonal antibodies, exert mainly systemic vascular 
effects partially via elevation of circulating adiponectin 
levels [257]. Interestingly, PPAR-α agonist and statins, 
which are frequently used in the treatment of cardiovas-
cular disease, have been shown to decrease adipose tissue 
inflammation by enhancing the action of adiponectin and 
inhibiting macrophage activation via the TLR4 signaling 
pathway [258–260]. Also, salicylates can promote mac-
rophage polarization into anti-inflammatory  (CD206+) 
M2 phenotype in WAT [261], and stabilize pre-existing 
atherosclerosis partly through inhibition of the NF-κB 
pathway [262]. In addition, dietary flavonoids and oes-
trogen have been suggested to alleviate inflammation in 
adipose tissue [263–265]. Whether the above approaches 
have direct effects on PVAT inflammation are remain 
unknown, and further investigations are needed to estab-
lish novel strategies to target local inflammation within 
PVAT.
Inhibition of renin–angiotensin–aldosterone system
The renin–angiotensin–aldosterone system (RAAS) is 
involved in systemic blood pressure regulation and in 
renal electrolyte homeostasis. Except for renin, all of the 
RAS system components are expressed in adipose tis-
sue [59]. Indeed, evidence has demonstrated the pres-
ence of local RAAS activity in PVAT [266]. AngII is the 
major component of RAAS with a variety of physiologi-
cal actions including vasoconstriction, stimulation of 
aldosterone release from the adrenal gland, renal sodium 
and water reabsorption, increase of blood pressure, cell 
growth, inflammation process, vascular and cardiac 
remodeling, activation of the sympathetic nervous sys-
tem, and ROS production [267]. Ang II exert its function 
through two main membrane receptors: the angioten-
sin type 1 receptor (AT1R) and the angiotensin type 2 
receptor (AT2R). The AT1R is responsible for most bio-
logical effects of Ang II such as pressure, trophic, and 
pro-inflammatory effects. Sakaue et  al. reported that 
ATR1 receptor in PVAT promotes vascular inflamma-
tion and aneurysm formation [268]. Previous research 
has reported angiotensin receptor blockers (ARBs) 
and angiotensin converting enzyme inhibitors (ACEI) 
reduced PVAT inflammation, which is associated with 
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the reduction of atherogenesis [269]. Furthermore, some 
ARBs are also able to act as partial PPAR-γ agonists, 
up-regulating adiponectin expression [270]. In addition 
to Ang II, aldosterone is also an important mediator of 
RAAS effects which can inhibit physiological insulin 
signaling and promote local inflammation via activation 
of T cells and macrophages [271]. Recent work verifies 
the direct action of aldosterone on adipose tissue was 
associated with metabolic syndrome, insulin resistance 
and a pro-inflammatory phenotype of the adipose tis-
sue utilizing an adipose tissue-specific mineralocorticoid 
receptor-overexpressing mouse model [272]. Mineralo-
corticoid receptor antagonists have revealed beneficial 
effects in terms of vascular redox state, systemic insulin 
sensitivity, vascular remodeling, endothelial function and 
AT inflammation [273–275]. Consequently, RAAS inhib-
itors such as ACEI, ARBs and aldosterone inhibitors may 
target adipose tissue to perform beneficial metabolic and 
cardiovascular effects.
AMPK activators
AMPK is a serine/threonine protein kinase involved in 
the regulation of metabolism, such as glucose transport, 
mitochondrial function, fatty acid oxidation and inflam-
mation [276]. AMPK is essential for the maintenance of 
cardiovascular health and several drugs commonly used 
for the treatment of CVD and metabolic diseases may 
also work through AMPK (e.g. statins, metformin and 
the TZD [277, 278]. Several studies revealed an irrefuta-
ble relationship between AMPK, obesity and inflamma-
tion [279, 280]. Activation of AMPK is known to exert an 
anti-inflammatory response via up-regulating IL-10 and 
down-regulation of TNF-α and IL-6. Abnormal lipid pro-
files and lipotoxicity, as seen in obesity and T2DM, pre-
dispose individuals to CVD. AMPK is a major regulator 
of lipid metabolism via stimulation of lipid oxidation [281, 
282]. Indeed, it was reported that PVAT induces vascu-
lar dysfunction via dysregulation of the AMPK/mam-
malian target of rapamycin (mTOR) pathway in high fat 
diet-induced obese rats [283]. Treatment of PVAT from 
rat thoracic aorta with AMPK activators AICAR, salicy-
late, metformin, resveratrol or diosgenin down-regulates 
the expression of proinflammatory cytokines (TNF-α, 
IL-6, MCP-1) and increases anti-inflammatory factors 
(adiponectin, PPAR-γ) in PVAT, which is associated with 
an increased eNOS phosphorylation and improved PVAT 
function [284, 285]. Thus, targeting AMPK in PVAT may 
have an anti-atherogenic therapeutic potential.
Conclusion
PVAT plays key tissue-specific roles during the 
development of atherosclerosis.  Under physiologi-
cal conditions, PVAT is able to store and combust 
lipids, generate heat and take up fatty acids from the 
blood.  PVAT also releases multiple vasoactive mole-
cules such as NO,  H2S and adiponectin, which protect 
against atherosclerosis development. Under patho-
physiological conditions (e.g. obesity, hyperlipidemia 
and diabetes), PVAT becomes dysfunctional. Together 
with reduced thermogenic capacity due to whiten-
ing of BAT-like PVAT, dysfunctional PVAT releases 
pro-inflammatory adipokines that promote endothe-
lial dysfunction, infiltration of inflammatory cells and 
migration of VSMC, subsequently promoting athero-
sclerosis development. Thus, targeting PVAT function 
is emerging as a novel therapeutic approach for the 
treatment of atherosclerosis that warrants validation in 
future research.
In summary, accumulating evidence indicate PVAT as 
a double-edged sword that possess both anti-atherogenic 
and pro-atherogenic effects under different conditions. 
Further study is needed to evaluate whether targeting 
PVAT function can be used as a novel approach for the 
treatment of atherosclerosis and subsequent CVD.
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